Skip to main content
EVGN
NASDAQ Industrial Applications And Services

Evogene Reports Worsening Q1 Financials Amidst Strategic Pivot and Nasdaq Delisting Risk

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.719
Mkt Cap
$9.005M
52W Low
$0.7
52W High
$2.42
52W Position info
2.7% above low
Off High info
70% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

EVGN is trading near its 52-week low of $0.7 (2.7% above the low).

Summary

Evogene reported a wider net loss and lower revenue in Q1 2026, largely due to warrant-related financing expenses, intensifying financial pressure as the company navigates Nasdaq delisting threats and a strategic shift.


Key Events · Earnings and Guidance · EVGN

  • Increased Net Loss

    Q1 2026 net loss widened to $5.9 million, up from $3.0 million in Q1 2025, primarily due to $3.8 million in financing expenses from a February 2026 warrant inducement.

  • Revenue Decline

    Revenues decreased significantly to $0.3 million in Q1 2026 from $2.3 million in the prior year, mainly due to lower seed sales from the Casterra subsidiary.

  • Cash Position & Burn

    The company ended Q1 2026 with $13.1 million in cash, cash equivalents, and short-term bank deposits, with a cash usage of $2.8 million for the quarter.

  • Strategic Collaborations

    Evogene announced three new collaborations in its pharma division focusing on inflammatory diseases, oncology, and demyelinating disorders, and continued progress with its ChemPass AI™ platform.


Analysis · EVGN · Industrial Applications And Services

Evogene's Q1 2026 results show a significant increase in net loss and a sharp decline in revenue, primarily driven by substantial financing expenses related to a recent warrant inducement. This financial deterioration occurs while the company is already facing Nasdaq delisting and has disclosed substantial doubt about its ability to continue as a going concern. While new collaborations in pharma and progress in its AI platform offer some strategic positives, the immediate financial performance and ongoing capital needs present significant challenges.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVGN was trading at $0.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.70 to $2.42. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVGN - Latest Insights

EVGN
Oct 06, 2026, 4:00 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.4101
Real-time Price: $0.371 info
Change: -$0.0391 (-10%) info
Market Cap: $6.698M info
EVGN
Sep 30, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4168
Real-time Price: $0.371 info
Change: -$0.0458 (-11%) info
Market Cap: $6.698M info
EVGN
Sep 28, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3907
Real-time Price: $0.371 info
Change: -$0.0197 (-5%) info
Market Cap: $6.698M info
EVGN
Sep 15, 2026, 5:15 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.5281
Real-time Price: $0.371 info
Change: -$0.1571 (-30%) info
Market Cap: $6.698M info
EVGN
Sep 11, 2026, 6:31 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $0.4728
Real-time Price: $0.371 info
Change: -$0.1018 (-22%) info
Market Cap: $6.698M info